Nanomedicine and macroscale materials in immuno-oncology

Sun, Qingxue; Barz, Matthias; Geest, Bruno G. De; Diken, Mustafa; Hennink, Wim E.; Kießling, Fabian; Lammers, Twan; Shi, Yang

doi:10.1039/c8cs00473k

Cited by 129 publications

(95 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For effective tumor immunotherapy, NP-based systems may combine different treatment modalities, such as chemotherapy, photodynamic therapy (PDT) and hyperthermia, as an effective therapeutic strategy. [61][62][63][64][65] Wang et al 54 Combined PD-L1 knockdown and PDT completely eliminated the B16-F10 tumors ( Figure 2E). Moreover, combined immunotherapy markedly suppressed the metastasis of B16-F10 in the lungs ( Figure 2F).…”

Section: Tumor Microenvironment-targeted Rna Interference Strategy mentioning

confidence: 91%

See 1 more Smart Citation

Non‐viral gene delivery for cancer immunotherapy

Wang

Saeed

Zhou

et al. 2019

The Journal of Gene Medicine

View full text Add to dashboard Cite

Recent decades have witnessed the revolutionary development of cancer immunotherapies, which boost cancer‐specific immune responses for long‐term tumor regression. However, immunotherapy still has limitations, including off‐target side effects, long processing times and limited patient responses. These disadvantages of current immunotherapy are being addressed by improving our understanding of the immune system, as well as by establishing combinational approaches. Advanced biomaterials and gene delivery systems overcome some of these delivery issues, harnessing adverse effects and amplifying immunomodulatory effects, and are superior to standard formulations with respect to eliciting antitumor immunity. Nucleic acid‐based nanostructures have diverse functions, ranging from gene expression and gene regulation to pro‐inflammatory effects, as well as the ability to specifically bind different molecules. A brief overview is provided of the recent advances in the non‐viral gene delivery methods that are being used to activate cancer‐specific immune responses. Furthermore, the tumor microenvironment‐responsive synergistic strategies that modulate the immune response by targeting various signaling pathways are discussed. Nanoparticle‐based non‐viral gene delivery strategies have great potential to be implemented in the clinic for cancer immunotherapy.

show abstract

Section: Tumor Microenvironment-targeted Rna Interference Strategy mentioning

confidence: 91%

“…For effective tumor immunotherapy, NP‐based systems may combine different treatment modalities, such as chemotherapy, photodynamic therapy (PDT) and hyperthermia, as an effective therapeutic strategy . Wang et al .…”

Section: Tumor Microenvironment‐targeted Rna Interference Strategy Fomentioning

confidence: 99%

Non‐viral gene delivery for cancer immunotherapy

Wang

Saeed

Zhou

et al. 2019

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

“…[255][256][257][258] In accordance with the mechanisms of antitumor immunity, immunotherapy can be divided into various classes, such as checkpoint inhibitors, cytokines for lymphocyte promotion, engineered T cells, and vaccines. [263] Platforms designed for combinations of cancer immunotherapy and nonsurgical treatment were reviewed in detail by Nam and colleagues. A safe and effective immunotherapy with great controllability and sensitivity can be achieved by developing novel drug delivery platforms based on nanotechnology and material science.…”

Section: Postoperative Immunotherapy For Long-term Antitumor Effectsmentioning

confidence: 99%

Advanced Nanotechnology Leading the Way to Multimodal Imaging‐Guided Precision Surgical Therapy

et al. 2019

View full text Add to dashboard Cite

Surgical resection is the primary and most effective treatment for most patients with solid tumors. However, patients suffer from postoperative recurrence and metastasis. In the past years, emerging nanotechnology has led the way to minimally invasive, precision and intelligent oncological surgery after the rapid development of minimally invasive surgical technology. Advanced nanotechnology in the construction of nanomaterials (NMs) for precision imaging-guided surgery (IGS) as well as surgery-assisted synergistic therapy is summarized, thereby unlocking the advantages of nanotechnology in multimodal IGS-assisted precision synergistic cancer therapy. First, mechanisms and principles of NMs to surgical targets are briefly introduced. Multimodal imaging based on molecular imaging technologies provides a practical method to achieve intraoperative visualization with high resolution and deep tissue penetration. Moreover, multifunctional NMs synergize surgery with adjuvant therapy (e.g., chemotherapy, immunotherapy, phototherapy) to eliminate residual lesions. Finally, key issues in the development of ideal theranostic NMs associated with surgical applications and challenges of clinical transformation are discussed to push forward further development of NMs for multimodal IGS-assisted precision synergistic cancer therapy.

show abstract

“…Nanomedicine and biomaterials are showing their increasing values and potential in cancer immunotherapy, which has led to an ever expanding and highly active research field in the last five years. [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] Nanomedicines and biomaterials have a long history of application in cancer drug therapy utilizing their ability to achieve tumor-targeted delivery and controlled drug release. In immuno-oncology, they have been used to modulate cancer immunity, for example, by nanomedicines targeting cancer cells, the immune microenvironment, and the peripheral immune system.…”

Section: Introductionmentioning

confidence: 99%

Clinical Translation of Nanomedicine and Biomaterials for Cancer Immunotherapy: Progress and Perspectives

Shi

2020

Advanced Therapeutics

Self Cite

View full text Add to dashboard Cite

Advances in immuno‐oncology have significantly improved cancer therapy outcomes. Unfortunately, potent responses to immunotherapy have only been achieved in subsets of patients. Nanomedicines and biomaterials have enormous potential for making immunotherapy work better in more patients, which has been suggested by a large number of preclinical studies. However, it remains unclear whether and how these materials will really benefit cancer patients treated by immunotherapy. Therefore, reviewing current clinical studies on nanomedicines and biomaterials in immuno‐oncology may provide valuable information for future translation research. In this work, the clinical landscape of cancer immunotherapy involving nanomedicines and biomaterials, mainly Abraxane, Doxil, messenger ribonucleic acid (mRNA) nanovaccines, and a biomaterial scaffold‐supported autologous vaccine, is reviewed. Clinical results demonstrate the high potential of nano/biomaterials in immunotherapy, achieved by rationalized utilization of their targeted delivery and reduced toxicities/side effects. Future clinical translation in this field will likely benefit from designing rational combinations of nanomedicines and biomaterials with the right immunotherapeutics applied in the right patients/tumors, and this should be achieved with the help of immune biomarker analysis. By rationally utilizing the unique features and advantages of nanomedicines and biomaterials, they will highly impact patient care in combination with immunotherapy.

show abstract

Nanomedicine and macroscale materials in immuno-oncology

Abstract: Nanomedicine and macroscale materials are increasingly impacting cancer immunotherapy.

Cited by 129 publications

References 140 publications

Non‐viral gene delivery for cancer immunotherapy

Non‐viral gene delivery for cancer immunotherapy

Advanced Nanotechnology Leading the Way to Multimodal Imaging‐Guided Precision Surgical Therapy

Clinical Translation of Nanomedicine and Biomaterials for Cancer Immunotherapy: Progress and Perspectives

Contact Info

Product

Resources

About